BACKGROUND Vitamin D (VD) may increase sirtuin 1 (SIRT1) and subsequently PPAR-γ coactivator 1α (PGC-1α) and irisin levels and these improvements may reduce insulin resistance (IR). The aim was to assess the effects of vitamin D supplementation on SIRT1, irisin, and IR in overweight/obese type 2 diabetes (T2D) patients. METHODS Ninety T2D males and females were recruited as a clinical trial study (mean of age and body mass index (BMI) of intervention and placebo groups were 50.05 ± 10.17 and 50.36 ± 10.2 yrs. and 31.37 ± 3.4 and 30.43 ± 3.2 kg/m2, respectively). The inclusion criteria were T2D, VD deficient, BMI > 25 kg/m2, and serum HbA1c < 8.5%. The exclusion criteria were using vitamin and mineral supplements, having any acute disease, recent modifying dose or type of drugs. The supplementation was 50,000 IU/week VD or placebo for 8 weeks. The demographic characteristics, anthropometrics, dietary intakes and physical activity status, sun exposure status, fasting blood sugar (FBS) and insulin, glycosylated hemoglobin (HbA1c), irisin, SIRT1, 25-hydroxy D3 (25(OH)VD), homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI) were determined. The significant P-value was ≤0.05. RESULTS The increase of serum VD, SIRT1, and irisin in the intervention group was significant (p < 0.001). HbA1c was decreased significantly by 1%. The changes in the other glucose indices (FBS, insulin, and IR) were non-significant. CONCLUSIONS VD supplementation may improve T2D by decreasing HbA1c and increasing SIRT1 and irisin in VD deficient T2D patients. Further trials are suggested. TRIAL REGISTRATION Iranian Registry of Clinical Trials, IRCT201604202365N11. Registered 21/08/2016, http://en.irct.ir/trial/2019.

中文翻译：

---

补充维生素D可改善超重或肥胖2型糖尿病患者的SIRT1，Irisin和葡萄糖指数：一项双盲随机安慰剂对照临床试验。

背景技术维生素D（VD）可能会增加瑟土因1（SIRT1），进而增加PPAR-γ共激活因子1α（PGC-1α）和虹膜素的水平，这些改善可能会降低胰岛素抵抗（IR）。目的是评估补充维生素D对超重/肥胖2型糖尿病（T2D）患者的SIRT1，虹膜素和IR的影响。方法招募90名T2D男性和女性作为临床试验研究对象（干预组和安慰剂组的年龄和体重指数（BMI）分别为50.05±10.17和50.36±10.2年，以及31.37±3.4和30.43±3.2 kg / m2 ， 分别）。纳入标准为T2D，VD缺乏，BMI> 25 kg / m2和血清HbA1c <8.5％。排除标准是使用维生素和矿物质补充剂，患有任何急性疾病，最近修改剂量或药物类型。补充是50 000 IU /周VD或安慰剂治疗8周。人口统计学特征，人体测量学，饮食摄入量和身体活动状态，日晒状态，空腹血糖（FBS）和胰岛素，糖基化血红蛋白（HbA1c），虹膜素，SIRT1、25-羟基D3（25（OH）VD），体内稳态模型确定胰岛素抵抗评估（HOMA-IR）和定量胰岛素敏感性检查指数（QUICKI）。显着P值≤0.05。结果干预组的血清VD，SIRT1和虹膜素升高显着（p <0.001）。HbA1c明显降低了1％。其他葡萄糖指数（FBS，胰岛素和IR）的变化无统计学意义。结论VD缺乏的T2D患者补充VD可以通过降低HbA1c并增加SIRT1和鸢尾素来改善T2D。建议进一步试验。试用注册伊朗临床试验注册，IRCT201604202365N11。注册于2016年8月21日，http：//en.irct.ir/trial/2019。